The Rel/NF-kB transcription factors play a key role in the regulation of apoptosis and in tumorigenesis by controlling the expressions of specific genes. To determine the role of the constitutive activity of RelA in tumorigenesis, we generated pancreatic tumor cell lines that express a dominant negative mutant of IkBa (IkBaM). In this report, we show that the inhibition of constitutive NF-kB activity, either by ectopic expression of IkBaM or by treating the cells with a proteasome inhibitor PS-341 which blocks intracellular degradation of IkBa proteins, downregulates the expression of bcl-xl. We identified two putative NF-kB binding sites (kB/A and B) in the bcl-xl promoter and found that these two sites interact with different NF-kB proteins. p65/p50 heterodimer interacts with kB/A site whereas p50/p50 homodimer interacts with kB/B. The bcl-xl promoter reporter gene assays reveal that NF-kB dependent transcriptional activation is mainly mediated by kB/A site, indicating that bcl-xl is one of the downstream target genes regulated by RelA/ p50. Both IkBaM and PS-341 completely abolish NF-kB DNA binding activity; however, PS-341, but not ectopic expression of IkBaM, sensitized cells to apoptosis induced by Taxol. This is due to the Taxol-mediated reactivation of RelA through phosphorylation and degradation of IkBb and the re-expression of NF-kB regulated bcl-xl gene in these cancer cells as ectopic expression of the bcl-xl gene confers resistance to Taxol-induced apoptosis in PS-341 sensitized cells. These results demonstrate the important function of various NF-kB/IkB complexes in regulating anti-apoptotic genes in response to apoptotic stimuli, and they raise the possibility that NF-kB : IkBa and NFkB : IkBb complexes are regulated by different upstream activators, and that NF-kB plays a key role in pancreatic tumorigenesis.
Introduction
The c-rel member of the Rel/NF-kB pleiotropic transcription factor family was first identified as a cellular homologue of the v-rel oncogene, suggesting that other Rel/NF-kB members are oncogenes (Verma et al., 1995; . The Rel/NF-kB family, which consists of RelA, Rel (v-rel) , RelB, p50 (p105) , and p52 (p100), and can form heterodimers and homodimers among themselves, controls the expression of numerous genes (Verma et al., 1995; . In most cell types, Rel/NF-kB proteins are sequestered in the cytoplasm in an inactive form through their noncovalent association with the inhibitor IkB (Sen and Baltimore, 1986) . This association masks the nuclear localization signal of Rel/NF-kB, thereby preventing Rel/NF-kB nuclear translocation and DNA binding activity (Baeuerle and Baltimore, 1989) . Stimulation of these cells leads to phosphorylation of IkBa, which triggers rapid degradation of the inhibitor, and consequently, Rel/NF-kB proteins are released and translocated into the nucleus, where they activate transcription of target genes (Verma et al., 1995; . One of the key target genes regulated by RelA is its inhibitor IkBa. We previously cloned IkBa cDNA and promoter and described a feedback inhibition pathway for control of IkBa gene transcription and downregulation of transient activation of Rel/ NF-kB activity (Chiao et al., 1994) . Activation of NFkB is achieved through the signal-induced proteolytic degradation of IkBs, which is mediated by the 26S proteosome (Chen et al., 1995; Brown et al., 1995; Mercurio et al., 1997) . Stimulation of cells by various inducers that leads to phosphorylation of IkBa at serine residues 32 and 36 by IkB kinases (IKKs) triggers the rapid degradation of the inhibitor (Woronicz et al., 1997; DiDonato et al., 1997; . Which kinases regulate IKK activity remains unclear; however, it appears likely that members of the MAP kinase kinase kinase (MAPKKK) family play a key role in control of IKK kinase complex. These findings have provided a useful tool for detailed functional analysis of components of an IkB kinase complex and a better understanding of the signal transduction cascade leading to activation of Rel/NFkB.
Several reports suggest that members of the Rel/NFkB and IkB families are involved in the development of cancer (Gilmore et al., 1996) . For instance, v-rel, carried by a highly oncogenic retrovirus, causes aggressive tumors in young birds and is able to transform avian lymphoid cells and fibroblasts (Moore and Bose, 1988; Sylla and Temin, 1986) . The mutated c-rel oncogene transforms cells (Moore and Bose, 1988) . The Tax protein from the leukemogenic virus HTLV-1 is a potent activator of Rel/NF-kB, and the growth of Tax-induced tumors in mice is inhibited by antisense RelA constructs (Kitajima et al., 1992) . Taxmediated activation of NF-kB resulted from direct interactions of Tax and MEKK1, a component of an IkB kinase complex leading to enhanced IkB kinase phosphorylation of IkBa (Yin et al., 1998) . In addition, the genes encoding c-Rel, Bcl-3, p105 (p50), and p100 (p52) are located at sites of recurrent genomic rearrangements in cancer (Gilmore et al., 1996) . Recently, we showed that RelA is constitutively activated in human pancreatic adenocarcinomas and in a number of human pancreatic tumor cell lines (Wang et al., 1999a) .
A major cause of death of mice that lack the RelA subunit of Rel/NF-kB transcription factors in embryonic development is a massive apoptosis of fetal liver cells; this suggests a role for RelA in protecting cells from pro-apoptotic stimuli (Beg et al., 1995) . This observation is supported by several recent reports showing that tumor necrosis factor a (TNFa) readily induced apoptosis in macrophages and a fibroblast cell line established from RelA knockout mice but not in wild-type cells (Beg et al., 1995) . This phenotype in RelA knockout cells could be inhibited by transfected RelA (Beg et al., 1995) . Similarly, radiation-, daunorubicin-or TNFa-induced apoptosis is potentiated in HT1080 human fibrosarcoma, human embryonic fibroblast, and Jurkat cell lines transfected with dominant negative IkBa (Wang et al., 1996; van Antwerp et al., 1996) . In our studies, expression of the dominant-negative IkBa mutant proteins did not enhance TNFa-induced apoptosis in cells that ectopically express high levels of Bcl-2 proteins, which did not inhibit RelA activation or RelA-dependent transactivation; this suggests that Bcl-2 functions downstream of the RelA anti-apoptotic signaling pathway (Herrmann et al., 1997 (Herrmann et al., , 1998 . We also showed that RelA and the RelA target genes uPA were constitutively activated in about 70% of human pancreatic cancers and nine of 11 human pancreatic cancer cell lines but not in normal pancreatic tissues and nontumorigenic pancreatic epithelial cells (Wang et al., 1999a,b) . Pancreatic adenocarcinoma is the fifth leading cause of adult cancer mortality in the US with 1 -2% survival rates in 5 years (DiGiuseppe et al., 1996) . Early detection of pancreatic cancer has not yet been developed; however, at the time of diagnosis, most pancreatic cancer patients present with locally advanced disease or metastasis. Resistance to apoptosis in human pancreatic cancer is thought to render most chemotherapeutic agents and radiation treatments ineffective (DiGiuseppe et al., 1996) . Thus, dysregulation of Rel/NF-kB activity in tumor cells may be critical in the inhibition of pro-apoptotic stimuli. We therefore undertook a study of the regulation of bcl-xl gene by NF-kB and the role of bcl-xl in control of apoptosis in pancreatic cancer cells.
Results
Constitutive RelA activity induced overexpression of Bcl-xl in human pancreatic cancer cell lines
We previously reported that RelA and the RelA target genes uPA were constitutively activated in about 70% of human pancreatic cancers and nine of 11 human pancreatic cancer cell lines but not in normal pancreatic tissues and nontumorigenic pancreatic epithelial cells (Wang et al., 1999a,b) . Interestingly, the levels of bcl-xl protein are increased in pancreatic cancer cell lines exhibiting constitutive RelA activity (Figure 1a,b) . As shown in Figure 1c , the constitutive RelA activity is found in the nuclear extracts from AsPc-1, MDAPanc-28, Capan-1 and Panc-1 cell lines, as we previously reported (Wang et al., 1999a,b) , but not in that of the E6E7 immortalized HPDE cells. Figure 1d shows that TNF-a-inducible RelA/p50 NFkB DNA binding activity in the E6E7 immortalized HPDE and Jurkat cell lines as controls for the constitutive activation of RelA in these pancreatic cancer cell lines.
In order to determine whether the constitutive RelA activity induced overexpression of bcl-xl, we constructed a retroviral-expressing Flag-tagged phosphorylation mutant of IkBa (S32, 36A) (IkBaM) to specifically inhibit RelA activity in the pancreatic cancer cells. Human pancreatic tumor cell lines AsPc-1, MDAPanc-28, Capan-1 and Panc-1 cells were infected with Flag-tagged IkBaM and control retrovirus and selected for the resistance to puromycin (800 ng/ml). The pooled AsPc-1 and MDAPanc-28 puromycin-resistant cells were used for our study. The expression of Flag-tagged IkBaM was detected in these cells infected by Flag-tagged IkBaM retrovirus but not in those infected by control retrovirus (Figure 2a ). The constitutive RelA activity was inhibited by IkBaM ( Figure 2b ). As shown on Western blot analysis (Figure 2c,d ), the expression of bcl-xl was also inhibited in cells that expressed Flag-tagged IkBaM but not in the control cells. The results suggest that constitutive RelA results in upregulation of bcl-xl in these pancreatic cancer cell lines. To verify this finding, we performed Northern blot analysis using AsPc-1/ CTL/puro, AsPc-1/Flag-tagged IkBaM, MDAPanc-28/ CTL/puro, MDAPanc-28/Flag-tagged IkBaM cells (Figure 2e,f) . Taken together, these results provide consistent evidence that bcl-xl could be induced by constitutive RelA in these pancreatic cancer cells.
The promoter of bcl-xl contains multiple kB enhancers and is regulated by RelA/p50 heterodimers We next identified two kB enhancers in the 800-bp promoter sequence of the human bcl-xl gene. The diagram shows that two kB enhancer sites (GGGGACTGCCcagggaGTGACTTTCC) are located 341-and 365-nt upstream of the bcl-xl translation start site and between 759 and 784 upstream of the transcription start site of the bcl-xl gene ( Figure 3a ). Sequence analysis revealed that the presence of the TATA box is located 25-bp upstream of the transcription initiation site and other previously identified cisregulatory elements (Figure 3a ). To determine with which members of Rel/NF-kB these two kB sites (kB/A and kB/B) in the bcl-xl promoter will interact, we synthesized oligonucleotides probe A, which only contains the kB/A site, and oligonucleotides probe B, which only contains the kB/B site and performed electrophoretic mobility shift assays to analyse the kB DNA-binding activity using these probes. As shown in Figure 3b , probe kB/A interacted with the RelA/p50 heterodimers as in the control using HIV/kB probe, whereas probe kB/B interacted with the p50/p50 homodimers. To confirm these differential binding activities, competition and supershift assays were carried out using wild-type and mutant kB/A and kB/B oligonuceotides and specific antibodies to RelA and p50. The analyses show that the kB/A site interacts with RelA/p50 heterodimers only and the kB/B site binds to p50/p50 homodimers (Figure 3c,d ). To determine whether these two kB sites (kB/A and kB/ B) identified in the bcl-xl promoter are functional, 800-bp and 520-bp genomic fragments of the bcl-xl gene promoter were cloned into pBLCAT3 vector ( Figure  3a ). By using PCR-mediated site-directed mutagenesis, mutant kB/A and kB/B sites were generated in the 520-bp fragment of the bcl-xl gene promoter (Figure 3a ). High levels of CAT activities were detected in COS cells cotransfected with the 800-bp or 520-bp bcl-xl gene promoter-CAT construct and the RelA/NF-kB expression vector ( Figure 3e , lanes 2 and 4). Little CAT activity increase was detected in the cells cotransfected with the bcl-xl gene promoter-CAT construct with the mutant kB/A site and the RelA/ NF-kB expression vector ( Figure 3e , lane 6), but increasing transactivation (twofold) was observed when These results show that the kB/A site, which binds to RelA/p50, is the key kB enhancer for regulating the expression of the bcl-xl gene, suggesting Figure 3 The promoter of bcl-xl contains multiple kB enhancers that are regulated by RelA/p50 heterodimers and p50/p50 homodimers. (a) Schematic diagram of bcl-xl promoter and bcl-xl promoter reporter gene constructs with wild-type and mutant kB/A and kB/B sequences indicated. (b) Electrophoretic mobility shift assay (EMSA) for NF-kB DNA binding activity with the kB probes using 10 mg of AsPc-1 cell nuclear extracts; lane 1, HIV-kB probe; lane 2 kB/A probe, lane 3, kB/B probe. (c) EMSA using 10 mg of AsPc-1 nuclear extracts with 32 P-labeled kB/A probe for the competition assay with wild-type and mutant kB/A oligonucleotides, and supershift with anti-RelA antibody with or without RelA peptide as indicated. (d) EMSA using 10 mg of AsPc-1 nuclear extracts with 32 P-labeled kB/B probe for competition assay with wild-type and mutant kB/B oligonucleotides, and supershift with anti-p50 antibody with or without p50 peptide as indicated. (e) Reporter gene assays for analysis of the bcl-xl promoter. Various bcl-xl CAT reporter gene constructs were transfected in COS cells with or without RelA expression plasmid that both kB/A and kB/B sites play important roles in regulating bcl-xl gene expression.
Taxol induced expression of bcl-xl via IkB kinase activated multiple NF-kB : IkB complexes
Since overexpression of the bcl-xl gene is regulated by RelA, it was of interest to determine whether down regulation of bcl-xl expression by inhibiting RelA DNA binding activity in human pancreatic cancer cells will confer the susceptibility to apoptosis induced by Taxol, which is one of the apoptosis-inducing chemotherapeutic agents used in the current treatment of pancreatic cancer. We therefore used various concentrations of Taxol to induce cell death in AsPc-1/IkBaM, MDAPanc-28/IkBaM and Panc-1/IkBaM cells at different time periods. MTT assays and FACS analysis (fluorescence activated cell sorting) showed that Taxol did not induce apoptosis in these cells (data not shown). To determine whether alternative signaling pathways are activated by Taxol to overcome the inhibition of RelA by dominant negative IkBa (IkBaM), further analyses were performed using AsPc-1/puro and AsPc-1/IkBaM stimulated with Taxol (40 mM) for 2 h. As shown in Figure 4a , the expression of a Flag-tagged IkBaM was confirmed. Interestingly, while Taxol enhanced the constitutive RelA/p50-DNA binding activity in AsPc-1/puro cells (Figure 4b , lanes 1 and 2, threefold induction by phosphoimage analysis), it reactivated RelA/p50 activity in AcPc-1/IkBaM cells (Figure 4b , lanes 3 and 4, threefold induction by phosphoimage analysis). Oct-1 DNA binding activity as loading control is shown in Figure 4c . These results suggest that RelA/p50 activity was activated from other IkB/RelA/p50 complexes by Taxol. To determine this possibility, immunoblot analyses for IkBa and IkBb were performed. The phosphorylated IkBa was detected in AsPc-1/puro cells with and without stimulation of Taxol (Figure 4d) , which is consistent with constitutive RelA activation in these cells. However, no phosphorylation of IkBa was observed in the AsPc-1/IkBaM cells, and the presence of the slower migrating Flag-tagged phosphorylation mutant of IkBa (S32, 36A) was detected (Figure 4e, lanes 3  and 4) . The Taxol MEF cells, suggesting that Taxol-induced RelA activation requires IKK activation ( Figure 5a ). As a control, NF-kB DNA binding activity induced by TNF-a was also analysed in these cells (Figure 5b ). This is consistent with previous reports that TNF-a and Taxol activated IKK2/b (Chen et al., 1995; Brown et al., 1995; Mercurio et al., 1997; Woronicz et al., 1997; DiDonato et al., 1997; Zandi et al., 1997; Blagosklonny et al., 1996; Heilker et al., 1999a) . Thus, the reactivation of bcl-xl expression by Taxol emphasizes the role of RelA-regulated bcl-xl expression in controlling apoptosis of human pancreatic cancer cells. Figure 5 Taxol-induced NF-kB activation is dependent on IkB kinase. The nuclear extracts were isolated for EMSA from IKK WT, IKK1/a 7/7 and IKK2/b 7/7 MEF cells unstimulated in both (a and b) lanes 1, 3 and 5, and stimulated with Taxol (10 mM) for 2 h in (a), or TNF-a (10 ng/ml) for 30 min in (b) lanes 2, 4 and 6
Proteosome inhibitor PS-341 suppressed constitutive RelA/p50 activity and bcl-xl expression
The proteosome inhibitor PS-341 was tested for time and dose dependent inhibition of constitutive RelA activity (Figure 6a ). The inhibition of constitutive RelA activity was observed at 100 nM of PS-341 at 4 h ( Figure  6a , lane 2), and RelA activity was completely inhibited in the cells treated with 10 nM PS-341 for 24 h ( Figure  6a, lane 8) . The Oct-1 DNA-binding activity was not altered in the presence of various concentrations of PS-341 over 4 to 48 h (Figure 6b) . Accompanied by the decreasing RelA DNA binding activity in the nucleus, the level of bcl-xl protein is also reduced by PS-341 (Figure 6c,d lanes 3 -6 and 9 -11) . Moreover, the expression of Bcl-xl and A20 mRNA is induced by Taxol and decreased by inhibition of RelA by PS-341 (Figure 7a ). These results suggest that inhibition of RelA constitutive activity by PS-341 in pancreas cancer cells may sensitize them to Taxol-induced cell death.
Taxol induced apoptosis in PS-341 sensitized pancreatic cancer cell lines with constitutive RelA activity
To determine whether inhibition of RelA constitutive activity in pancreas cancer cells by PS-341 sensitizes them to Taxol-induced cell death, AsPc-1 cells were treated with 10 nM PS-341 and 50 mM Taxol from 24 to 72 h and the numbers of viable cells were determined by MTT assays. As shown in Figure 8a , there was a fivefold survival reduction in the cells treated with PS-341 and Taxol compared with those treated with PS-341 or Taxol alone. The findings were similar for MDAPanc-28, Capan-1 and Panc-1 cells (data not shown). FACS analysis showed that Taxol-induced apoptosis in PS-341 sensitized AsPc-1 cells (Figure 8b ).
These results suggest that inhibition of RelA-regulated bcl-xl expression may render AsPc-1 pancreatic cancer cells predisposed to Taxol-induced apoptosis.
Ectopic expression of bcl-xl confers resistance to apoptosis in the pancreatic cancer cells treated with PS-341 and taxol
To determine the role of bcl-xl in PS-341-mediated sensitization to Taxol-induced pancreatic cancer cell apoptosis, we tested whether ectopic expression of bclxl cDNA would induce resistance to Taxol-mediated apoptosis in AsPc-1 cells. These cells were transfected with 0.5 mg of GFP expression vectors for labeling the cells and LacZ plasmid for transfection efficiency control in the presence and absence of 5 mg of bcl-xl expression plasmid. After 48 h, these cells were treated with PS-341 (10 nM), Taxol (50 mM), or both for 24 h, and FACS analysis was performed to determine the number of GFP positive cells (Figure 9 ). The analysis showed that the number of GFP-positive cells in PS-341-and Taxol-treated AsPc-1 cells with ectopic expression of bcl-xl gene was almost the same as the control AsPc-1 cells and AsPc-1 cells treated with PS-341 or Taxol, whereas the number of GFP-positive cells in PS-341-and Taxol-treated AsPc-1 cells without a transfected bcl-xl gene was significantly reduced (Figure 9 ). These combined results suggest that overexpression of bcl-xl confers resistance to Taxol-induced apoptosis in PS-341-sensitized pancreatic cancer cells.
Discussion
The transcription factor NF-kB plays a critical role in controlling expression of its downstream target genes in immune and inflammatory responses, development, and apoptosis (Verma et al., 1995; Gilmore et al., 1996) . Important advances have been made in understanding the signal transduction cascades that control NF-kB activation in response to proinflammatory cytokines such as TNF-a and IL-1. Several lines of evidence indicate that the transcription factor NF-kB is constitutively activated in cancer cells, suggesting that NF-kB plays an important role in tumorigenesis (Verma et al., 1995; ; however, the downstream target genes regulated by NF-kB in the tumorigenic process remain to be identified. The current study sought to determine and characterize the expression of bcl-xl regulated by RelA activity and the role of bcl-xl in regulation of apoptosis induced by Taxol in human pancreatic cancer cells, which are resistant to apoptosis induced by most chemotherapeutic agents and radiation (DiGiuseppe et al., 1996) . This ineffectiveness in the treatment of pancreatic adenocarcinoma in part results in this disease being the fifth leading cause of adult cancer mortality in the US.
We have demonstrated that bcl-xl plays a key role in the control of apoptosis and transcription of bcl-xl is induced by constitutive RelA/NF-kB activity in human pancreatic cancer cells. The induction of bcl-xl is likely mediated directly by the kB sites present in the upstream promoter element of the bcl-xl gene. Furthermore, IkBaM-inhibited transcription of bcl-xl is reinduced by p65(RelA) from other IkB/NF-kB complexes such as IkBb/p65(RelA) complex through Taxol-mediated phosphorylation and degradation of IkBb in the pancreatic cancer cells expressing IkBaM. These results demonstrate the importance of various NF-kB/IkB complexes in regulation of antiapoptotic genes in cancer cells.
We previously showed that RelA and its downstream target gene uPA are constitutively activated in human pancreatic adenocarcinomas and in a number of human pancreatic tumor cell lines (Wang et al., 1999a,b) . To determine the role of constitutive RelA in pancreatic cancer cells, we generated several cell lines expressing IkBaM by retroviral infections. We have shown that the constitutive NF-kB activity is efficiently abrogated either by ectopic expression of IkBaM or by treating the cells with PS-341, an inhibitor of proteosome responsible for the intracellular degradation of IkB proteins. Blocking of constitutive NF-kB activity by either IkBaM or PS-341 inhibits the expression of bcl-xl (Figure 2) . We identified the two putative NF-kB binding sites (kB/A and B) in the bcl-xl promoter. Bclxl promoter reporter gene assays indicate that the NFkB-dependent transcriptional activation is mainly mediated by the kB/A site, indicating that bcl-xl is one of the downstream target genes regulated by RelA/ p50. Several investigators have recently reported the regulation of bcl-xl gene expression by RelA/p50 (Glasgow et al., 2000; Chen et al., 2000; Stroka et al., 1999; Bui et al., 2001; Tsukahara et al., 1999) . In this report, we have shown that the promoter of bcl-xl gene contains two different kB sites, kB/A and kB/B, and, hence, is a target of various NF-kB complexes. The RelA/p50 heterodimers interact with the kB/A site whereas the p50/p50 homodimers interacts with the kB/ B site. It has been shown that the p65(RelA)/p50 heterodimers play a key role in activation of transcription of NF-kB downstream target genes; however, p50/ p50 homodimers appear to function as transcriptional Figure 9 Expression of exogenous bcl-xl protects against PS-341-and Taxol-mediated apoptosis. AsPc-1 cells were grown in 6-well dishes and transfected with GFP and LacZ expression plasmids in the presence and absence of bcl-xl expression plasmids. Twentyfour hours after transfection, these AsPc-1 cells were treated with Taxol (50 mM), PS-341 (10 nM), or both for 24 h, and the number of GFP-positive cells were determined by FACS analysis and transfection efficiencies were normalized by LacZ activity activators or repressors, depending on the cell type (Ishikawa et al., 1996 (Ishikawa et al., , 1998 . Our results from reporter gene assay (Figure 3f ) suggest that both kB/A and kB/B sites in bcl-xl promoter play an important role in the control of the expression of this key apoptotic mediator and p50/p50 homodimers may positively be involved in the bcl-xl expression. PS-341-mediated time dependent inhibition of bcl-xl expression suggested that the halflife of bcl-xl protein is greater than 4 h, which is consistent with a previous report (Pardo et al., 2002) . Ectopic expression of bcl-xl confers resistance to Taxolinduced apoptosis in PS-341 sensitized cells. These results clearly demonstrate the importance of various NF-kB/IkB complexes in regulation of anti-apoptotic genes.
IkBaM and PS-341 completely abolish the RelA constitutive activity in the pancreatic cancer cells (Figure 2) . However, PS-341, but not ectopic expression of IkBaM, sensitized cells to apoptosis induced by Taxol (Figures 8 and 9 ). Several reports showed that Taxol activated NF-kB via IKK2/b, and IkBa, IkBb and IkBe complexes are the substrates of IKK2/b (Lee et al., 1997; Jordan et al., 1996; Blagosklonny et al., 1996; Heilker et al., 1999a,b) . The reactivation of RelA induced by Taxol in pancreatic cancer cells that express IkBaM occurred through phosphorylation and degradation of IkBb, resulting in the re-expression of the NF-kB regulated bcl-xl gene in these cancer cells (Figures 4 and 6) . These results are consistent with our finding that TNF-a increased constitutive RelA DNA binding activity in pancreatic cancer cells and induced RelA DNA-binding activity in the pancreatic cancer cells that express IkBaM (data not shown). The expression of both NF-kB downstream target gene bclxl and A20 was significantly reduced by a NF-kB inhibitor, PS-341, in the presence and absence of Taxol stimulation (Figure 7 , lane 3 and 4), further supporting that PS-341 is a potent inhibitor for NF-kB activation by blocking the degradation of IkBs. Our data obtained using stable clones pooled from the infection of control and IkBaM retrovirus suggest that inhibition of NF-kB activity by IkBaM may not be sufficient to block the bcl-xl expression after Taxol stimulation, because other IkB/NF-kB complexes such as IkBb/NF-kB complex can be activated to induce bcl-xl expression. Therefore, sensitization of pancreatic cancer cell lines to apoptosis induced by anti-cancer agents such as Taxol (Figures  7 -9 ) requires complete inhibition of NF-kB activation by blocking degradation of both IkBa and IkBb proteins. This is consistent with the important role of NF-kB in control of apoptosis. Our results suggest that inhibiting the degradation of IkBs is critical in order to suppress NF-kB activation induced by various anticancer agents.
In summary, the current study provides direct evidence that bcl-xl is one of the downstream target genes regulated by RelA in pancreatic cancer cells and the bcl-xl plays a key role in control of Taxol-induced apoptosis in pancreatic cancer cells. Multiple p65RelA/ IkB complexes are activated in response to the apoptotic signal induced by Taxol and result in the re-expression of the NF-kB regulated bcl-xl gene in pancreatic cancer cells. Furthermore, we identified the two putative NF-kB binding sites (kB/A and B) in the bcl-xl promoter, and these two sites interact with different NF-kB heterodimers and homodimers in regulating bcl-xl gene expression. Taken together, our results suggest the importance of various NF-kB/IkB complexes in regulating anti-apoptotic genes.
Materials and methods

Cell culture
The human pancreatic adenocarcinoma cell lines AsPc-1, Capan-1, and Panc-1 were obtained from the American Type Cell Culture (Rockville, MD, USA). MDAPanc-28 cells were obtained from Dr Marsha L Frazier (M.D. Anderson Cancer Center). IKK +/+ , IKK1/a 7/7 and IKK2/b 7/7 MEF cells were provided by Dr Inder M Verma (Salk Institute, La Jolla, CA, USA). All cells were cultured in Dulbecco's modified Eagle's medium (DMEM) (Gibco BRL, Gaithersburg, MD, USA) containing 10% fetal bovine serum, 100 U/ ml penicillin (Gibco BRL) and 10 mg/ml streptomycin (Gibco BRL) in a 378C incubator at 5% CO 2 atmosphere.
Retroviral infections of human pancreatic cancer cell lines
The CMV-Flag-IkBaM/puro r retroviral vector was generated by replacing the XhoI -HindIII fragment containing the TRE minCMV promoter and rTTA sequence of the pRetro-On/ puro r with XhoI -BamHI fragment of CMV-Flag-mutant IkBa (IkBaM). The CMV-IkBaM was provided by Dr Inder M Verma (Salk Institute, La Jolla, CA, USA). The CMVFlag-IkBaM/puro r and pRetro-On/puro r control retroviruses were generated and infections were performed as described previously (Naviaux et al., 1996) . Forty-eight hours after infection, pancreatic cancer cell lines were seeded in a 100-mM dish at a density of 5610 5 cells in the culture medium containing 500 mg puromycin (Clontech, Palo Alto, CA, USA). Both control and IkBaM puromycin-resistant pancreatic cancer cells were pooled for Flag-tagged IkBaM expression analysis.
Western blot analysis
Cytoplasmic extracts were prepared as described by Andrews and Faller (1991) . Samples were denatured and subjected to 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS -PAGE). The resolved proteins were transferred to an Immobilon-P membrane (Millipore, Bedford, MA, USA). The membrane was blocked with 5% nonfat milk in phosphate-buffered saline (PBS) containing 0.2% Tween-20 and incubated with affinity-purified mouse antibody against Flag epitope, b-actin, rabbit antibody against IkBa, IkBb, RelA (65), or bcl-xl (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA). Membranes were washed in PBS containing 0.2% Tween-20 and probed with horseradish peroxidasecoupled secondary goat anti-rabbit or mouse IgG antibodies (Amersham, Arlington Heights, IL, USA). Proteins were detected using a chemoluminescence kit (Amersham).
Northern blot analysis
Total RNA was isolated from the pancreatic cancer cell lines by the acid guanidium thiocyanate phenol chloroform extraction, as described by Chomczynski and Sacchi (1987) .
